prevalence of microsatellite and KRAS status in stage IV CRC using a large-scale US national database and assessed their effect on outcomes of patients with CRC. Materials and Methods This study received approval from the Yale School of Medicine
Search Results
Johannes Uhlig, Michael Cecchini, Amar Sheth, Stacey Stein, Jill Lacy, and Hyun S. Kim
Jane Apperley
to have functions that may be important in gonadal development, implantation, and fetal development. 1 - 5 An international registry of pregnancy outcome was recently established by Novartis to compile pregnancy outcomes in women who have been
Sumer K. Wallace, Jeff F. Lin, William A. Cliby, Gary S. Leiserowitz, Ana I. Tergas, and Robert E. Bristow
in patients with ovarian cancer Describe the impact on patient outcomes related to refusal of recommended chemotherapy in patients with ovarian cancer Background Ovarian cancer remains the deadliest gynecologic malignancy, with
John B. Eifler, Daniel A. Barocas, and Matthew J. Resnick
) remains low, and selecting the subset of patients most likely to benefit from NAC has proven difficult. Patients with organ-confined MIBC have experienced excellent oncologic outcomes absent the use of NAC (5-year disease-specific survival of ≈80%). 12
Anna M. Gibson and Claire Sutherby
Introduction: Chemotherapy-induced febrile neutropenia is a medical emergency. Delays in time to appropriate broad spectrum antibiotic therapy significantly increase morbidity and mortality. The purpose of this project is to improve outcomes in
Hinda Boutrid, Maryam Lustberg, Jeffrey Vandeusen, Sagar Sardesai, Daniel Stover, Robert Wesolowski, Mathew Cherian, Julie Stephens, Marilly Palettas, Evan Morgan, Mohmoud Kassem, Michael Berger, Craig A. Vargo, Bhuvaneswari Ramaswamy, and Nicole Williams
outcomes and treatment strategies of metastatic ILC. This retrospective study evaluates the overall survival (OS) and progression-free survival (PFS) in the metastatic ILC population at a single institution, focusing on first line treatment received in the
Radhakrishnan Ramchandren, Stephen M. Ansell, Philippe Armand, Andreas Engert, Fiona Taylor, Kim Cocks, Clara Chen, Bryan Bennett, Alejandro Moreno-Koehler, Adam Roeder, Anne Sumbul, Mariana Sacchi, and David Cella
checkpoint inhibitor monoclonal antibody, demonstrated efficacy and clinically meaningful improvement in pt-reported outcomes (PROs) in pts with relapsed/refractory cHL in cohorts A, B, and C of CheckMate 205 (NCT02181738) (Armand et al, J Clin Oncol 2018
Matthew Loscalzo, Karen Clark, Jeff Dillehunt, Redmond Rinehart, Rex Strowbridge, and Daniel Smith
authors have taken this process a step further by automating biopsychosocial screening through the use of touch-screen technology. 12 SupportScreen Improved Patient Outcomes “At Your Fingertips” The authors' team developed a new touch screen
Stephanie J. Lee
multiple myeloma . N Engl J Med 2003 ; 348 : 1875 – 1883 . 6 American Society of Clinical Oncology . Outcomes of cancer treatment for technology assessment and cancer treatment guidelines . J Clin Oncol 1996 ; 14 : 671 – 679 . 7
Ali A. Mokdad, Amit G. Singal, Jorge A. Marrero, Hao Zhu, and Adam C. Yopp
for HCC remains below 20% in the United States. 2 Poor HCC outcomes are largely attributed to low rates of HCC surveillance and high rates of late stage diagnosis. 3 , 4 Accurate HCC staging is important for patient prognostication, treatment
